Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments
You may also be interested in...
Emerging Markets Slowdown Trips Up Lilly’s 2014 Revenue Estimates
Lilly says emerging markets represent “clear and significant opportunity” despite recent difficulties.
As India’s Diabetes Market Grows, Eli Lilly Brings In A New Leader
With an eye on diabetes and non-communicable diseases, Lilly taps new leadership in India.
Lessons From Galvus: Novartis Teams Up With India’s Lupin To Market COPD Drug Onbrez
Novartis will compete against market leader Cipla to make a dent in the emerging Indian COPD space.